Navigation Links
Symphogen Announces the Appointment of Annika Espander Jansson as Non-Executive Director

COPENHAGEN, Denmark, December 20, 2013 /PRNewswire/ --

Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today announces the appointment of Annika Espander Jansson as a Non-Executive Director of the Board, with effect from 19 December 2013.

Annika has over twenty years' experience in the healthcare sector, both as a sell-side analyst and investor. She has a proven track record in strategic development of businesses and broad experience in managing operations in different segments of the financial markets.

Annika began her career as Equity Analyst and Sector Head of Healthcare at Aros Securities in Stockholm 1994-1996, followed by similar roles at Enskilda Securities, where she was Sector Head of Equity Research in Healthcare for five years, and Handelsbanken Capital Markets, where she gained experience of the financial services sector and became Group Head of Private Banking.  She joined Catella Healthcare, a private venture capital investor in healthcare companies, in 2004 as Managing Partner of a small team of professionals, during which time the IRR of the company's portfolio exceeded 35%.  Annika returned to Handelsbanken as Global Head of Private Banking in September 2010-June 2013 during which time the bank's ranking was upgraded to No. 1, according to the influential client survey - Prospera.

Annika is currently the founder and CEO of Asperia, a strategic and business advisory firm in the healthcare and financial services sectors. She is also a Board member of the public companies Stille AB and Probi AB, private portfolio companies Attana AB, Cellartis AB and Duocort AB, as well as the Swedish Financial Analyst Organisation. Annika holds a Ph.D. from the University of Gothenburg.

Welcoming the appointment, Göran Ando MD, Chairman of the Board, commented: "I am delighted to welcome Annika to Symphogen. Annika's extensive experience in both the healthcare industry and financial markets makes her a perfect addition to the Board.  Annika's skills, knowledge and experience will be invaluable to furthering the success of Symphogen."

Annika Espander Jansson added: "I am very excited to take part in the development of Symphogen which operates in a very important medical area with significant unmet medical needs and with a business concept aiming at improving therapies for cancer patients."

About Symphogen A/S  

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market.

The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its oncology pipeline and has currently brought two product candidates into the clinic. The company's productive technology suite - capable of identifying, selecting and manufacturing optimal antibody mixtures - fuels Symphogen's innovative pipeline.

The lead oncology product, Sym004, was out-licensed to Merck KGaA in 2012 following phase 2 clinical data in late stage cancer patients.

In total, the company has raised €249 million in equity capital from premier international investors including Novo, Essex Woodlands Health Ventures and PKA, and employs 95 people, most of whom are based at Symphogen's facilities in Copenhagen.

For additional information, please contact:
Kirsten Drejer
Chief Executive Officer
Phone: +45-22-10-99-59

Martin Olin
Chief Financial Officer
Phone: +45-40-21-85-32

Annes Associates
Shari Annes
Phone: +1-650-888-0902

Consilium Strategic Communications
Mary-Jane Elliott, Amber Bielecka
Phone: +44-207-920-2354

SOURCE Symphogen
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Symphogen Grants Exclusive Worldwide License of Phase II Oncology Drug Candidate Sym004 to Merck KGaA
2. Lineagen Announces $3.5 Million Series C Round and Close of Series B Financing
3. Amgen Announces Positive Top-Line Results From Phase 3 MENDEL-2 Trial Of Evolocumab (AMG 145) In Patients With High Cholesterol
4. Asmacure Announces Clinical Update for ASM-024 DPI in Two Phase 2 Trials
5. China Cord Blood Corporation Announces Results of 2013 Annual General Meeting
6. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option
7. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
8. Pittcon Announces the 2014 Technical Program
9. AudioNotch Tinnitus Treatment Announces Holiday Sale
10. Spotlight Innovation, Inc. Announces Name Change and Closing of Merger
11. DryLet, LLC Announces Investment from Ronald A. Chisholm Limited to Support Growth and Expansion
Post Your Comments:
(Date:10/9/2015)... Oct. 9, 2015  Pulmatrix, Inc., (NASDAQ: PULM ) ... investor conferences. th Annual BIO Investor ... (2:00 pm EDT). --> th Annual ... am PDT (2:00 pm EDT). --> Pulmatrix ... Growth Stock Conference on Thursday, October 15, 2015 at 8:30 ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup uBiome today ... understand the relationship between weight management and the microbiome. The study uses the ResearchKit ... using an iPhone app. , The uBiome app is available as a free download ...
(Date:10/8/2015)... Fla. , Oct. 8, 2015   Intrexon ... synthetic biology, today announced the appointment of Joseph ... Environment Sector, succeeding Nir Nimrodi who continues ... Vaillancourt will direct Intrexon,s endeavors to generate sustainable, biologically ... America , where he held a variety of ...
(Date:10/8/2015)... , Oct. 8, 2015  Genetic testing for mutations ... the identification of more couples at risk of having ... presented today at the 2015 American Society of Human ... in Baltimore, Maryland . The study ... (NYSE: DGX ) are presenting at the conference ...
Breaking Biology Technology:
... (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... , , ... ... ...
... ... Be Discussed and Demonstrated at Philadelphia Conference , ... Chicago, IL (PRWEB) March 11, 2010 -- ClearTrial, the ... panel discussion which includes pharmaceutical analysts from Deutsche Bank and Cowen & Company at ...
... TORONTO , March 11 /PRNewswire/ - Trillium Therapeutics ... announced that it has entered into two definitive license agreements ... Children (SickKids) in Toronto, Ontario , granting Trillium exclusive ... of hematopoietic stem cell transplantation and cancer. , ...
Cached Biology Technology:
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/6/2015)... LAKE CITY , Oct. 6, 2015 ... company, announced today that it has signed a contract ... monitoring services across the full range of sentences under ... Group,s President of the Americas. "This contract with the ... region of the US and advances our position as ...
(Date:10/5/2015)... ) releases the following ... NXTD ), a biometric authentication company focused on the ... ) releases the following market and company update ... authentication company focused on the growing mobile commerce market. ... ) releases the following market and company update ...
Breaking Biology News(10 mins):
... the most commonly cultivated cacao plant in the world ... this week. Researchers have utilised high quality DNA sequences to ... markers that can lead to higher yielding cocoa plants that still ... the cacao tree ( Theobroma cacao L. ...
... species, according to a new study led by Woods ... published in the journal PLOS ONE . Because ... may have far-reaching effects on the ocean environment and ... the center of the ocean ecosystemnearly all animals are ...
... insecurity increases the risk of death among injection drug ... life-prolonging antiretroviral therapy (ART), according to a new study ... the peer-reviewed science journal, PLoS One , examines ... among injection drug users. Food insecurity is defined by ...
Cached Biology News:
... Software reads and processes raw ... microarray data for analysis. ... one 2-year license for Feature ... , * one CD-ROM ...
... imported for data analysis , Automatic grid, subgrid ... template assignment , ... Extensive background and signal options to optimize, ... results , ...
... DNA Gel Stain combo offers these benefits: ... products separately Offers a ... Eliminates risks to yourself, the environment ... from 100 bp to >30 kb. UltraPure Agarose is ...
... stocks contained in standard 96-well microtiter plates. ... approximately 5,000 clones per plate. After positive ... the corresponding subplate is screened with a ... well(s). Cells from a positive well are ...
Biology Products: